{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T08:48:08Z","timestamp":1784882888025,"version":"3.55.0"},"reference-count":33,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2016,11,25]],"date-time":"2016-11-25T00:00:00Z","timestamp":1480032000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2016,11,25]],"date-time":"2016-11-25T00:00:00Z","timestamp":1480032000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1111\/jcpt.12479","type":"journal-article","created":{"date-parts":[[2016,11,26]],"date-time":"2016-11-26T04:32:43Z","timestamp":1480134763000},"page":"18-26","source":"Crossref","is-referenced-by-count":37,"title":["The optimal single-dose regimen of rasburicase for management of tumour lysis syndrome in children and adults: a systematic review and meta-analysis"],"prefix":"10.1155","volume":"42","author":[{"given":"X.","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Pharmacy; Beijing Children's Hospital; Capital Medical University; Beijing China"},{"name":"Department of Pharmacy Administration and Clinical Pharmacy; School of Pharmaceutical Sciences; Peking University Health Science Center; Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Administration and Clinical Pharmacy; School of Pharmaceutical Sciences; Peking University Health Science Center; Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Nie","sequence":"additional","affiliation":[{"name":"Department of Pharmacy; Beijing Children's Hospital; Capital Medical University; Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Administration and Clinical Pharmacy; School of Pharmaceutical Sciences; Peking University Health Science Center; Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Administration and Clinical Pharmacy; School of Pharmaceutical Sciences; Peking University Health Science Center; Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy; Beijing Children's Hospital; Capital Medical University; Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy; Beijing Children's Hospital; Capital Medical University; Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,11,25]]},"reference":[{"key":"10.1111\/jcpt.12479-BIB0001|jcpt12479-cit-0001","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1586\/17474086.2016.1127156","article-title":"Tumor lysis syndrome: review of pathogenesis, risk factors and management of a medical emergency","volume":"9","author":"Criscuolo","year":"2016","journal-title":"Expert Rev Hematol"},{"key":"10.1111\/jcpt.12479-BIB0002|jcpt12479-cit-0002","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1055\/s-0035-1549846","article-title":"A focused review of the pathogenesis, diagnosis, and management of tumor lysis syndrome for the interventional radiologist","volume":"32","author":"Friedman","year":"2015","journal-title":"Semin Intervent Radiol"},{"key":"10.1111\/jcpt.12479-BIB0003|jcpt12479-cit-0003","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1365-2141.2010.08143.x","article-title":"Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus","volume":"149","author":"Cairo","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1111\/jcpt.12479-BIB0004|jcpt12479-cit-0004","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1200\/JCO.2007.15.0177","article-title":"Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review","volume":"26","author":"Coiffier","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1111\/jcpt.12479-BIB0005|jcpt12479-cit-0005","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.1200\/JCO.2003.04.115","article-title":"Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study","volume":"21","author":"Coiffier","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1111\/jcpt.12479-BIB0006|jcpt12479-cit-0006","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/bjh.12542","article-title":"Rasburicase in the prevention of laboratory\/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children's Oncology Group Report","volume":"163","author":"Galardy","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1111\/jcpt.12479-BIB0007|jcpt12479-cit-0007","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.anpedi.2009.10.011","article-title":"Rasburicase versus allopurinol in the treatment of hyperuricaemia in tumour lysis syndrome","volume":"72","author":"Tatay","year":"2010","journal-title":"An Pediatr"},{"key":"10.1111\/jcpt.12479-BIB0008|jcpt12479-cit-0008","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/cncr.11612","article-title":"Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study","volume":"98","author":"Bosly","year":"2003","journal-title":"Cancer"},{"key":"10.1111\/jcpt.12479-BIB0009|jcpt12479-cit-0009","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1600-0609.2010.01457.x","article-title":"A single, fixed dose of rasburicase (6 mg maximum) for treatment of tumor lysis syndrome in adults","volume":"85","author":"Giraldez","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1111\/jcpt.12479-BIB0010|jcpt12479-cit-0010","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/1078155210364180","article-title":"Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome","volume":"17","author":"Knoebel","year":"2011","journal-title":"J Oncol Pharm Pract"},{"key":"10.1111\/jcpt.12479-BIB0011|jcpt12479-cit-0011","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1592\/phco.28.6.685","article-title":"Evaluation of a single fixed dose of rasburicase 7.5 mg for the treatment of hyperuricemia in adults with cancer","volume":"28","author":"Reeves","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1111\/jcpt.12479-BIB0012|jcpt12479-cit-0012","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/jcpt.12061","article-title":"Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis","volume":"38","author":"Feng","year":"2013","journal-title":"J Clin Pharm Ther"},{"key":"10.1111\/jcpt.12479-BIB0013|jcpt12479-cit-0013","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/1078155214520821","article-title":"Fixed, low-dose rasburicase for the treatment or prevention of hyperuricemia in adult oncology patients","volume":"21","author":"Herrington","year":"2015","journal-title":"J Oncol Pharm Pract"},{"key":"10.1111\/jcpt.12479-BIB0014|jcpt12479-cit-0014","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/bmt.2010.212","article-title":"Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies","volume":"46","author":"Trifilio","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1111\/jcpt.12479-BIB0015|jcpt12479-cit-0015","first-page":"1","article-title":"Single 4.5 mg fixed-dose of rasburicase for hyperuricemia associated with tumor lysis syndrome","volume":"22","author":"Patel","year":"2016","journal-title":"J Oncol Pharm Pract"},{"key":"10.1111\/jcpt.12479-BIB0016|jcpt12479-cit-0016","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/phar.1198","article-title":"Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome","volume":"33","author":"McBride","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1111\/jcpt.12479-BIB0017|jcpt12479-cit-0017","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1093\/annonc\/mdr490","article-title":"A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome","volume":"23","author":"Vadhan-Raj","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1111\/jcpt.12479-BIB0018|jcpt12479-cit-0018","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1345\/aph.1P296","article-title":"Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients","volume":"44","author":"Vines","year":"2010","journal-title":"Ann Pharmacother"},{"key":"10.1111\/jcpt.12479-BIB0019|jcpt12479-cit-0019","first-page":"142","article-title":"Single dose rasburicase reduces the financial toxicity and prevents tumour lysis syndrome in children with high tumour burden","volume":"1731","author":"Syrimi","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1111\/jcpt.12479-BIB0020|jcpt12479-cit-0020","unstructured":"Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0 (updated March 2011) http:\/\/www.cochrane-handbook.org"},{"key":"10.1111\/jcpt.12479-BIB0021|jcpt12479-cit-0021","unstructured":"Wells GA Shea B O'connell D Peterson JEA Welch V Losos M Tugwell P The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-analyses http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.htm"},{"key":"10.1111\/jcpt.12479-BIB0022|jcpt12479-cit-0022","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.ajkd.2013.02.378","article-title":"Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis","volume":"62","author":"Lopez-Olivo","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/jcpt.12479-BIB0023|jcpt12479-cit-0023","unstructured":"Evidence-based Medicine Open Meta-Analyst - The Tool www.brown.edu\/academics\/public-health\/research\/evidence-based-medicine\/index.php?q=open-meta-analyst-tool"},{"key":"10.1111\/jcpt.12479-BIB0024|jcpt12479-cit-0024","first-page":"S84","article-title":"Single dose\/single vial rasburicase in the management of paediatric patients with hyperuicemia\/tumor lysis syndrome","volume":"602","author":"Dwivedi","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1111\/jcpt.12479-BIB0025|jcpt12479-cit-0025","first-page":"S8","article-title":"A single dose of rasburicase is sufficient for treatment of hyperuricemia in children: case series with review of literature","volume":"602","author":"Martin","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1111\/jcpt.12479-BIB0026|jcpt12479-cit-0026","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1743-7563.2011.01464.x","article-title":"Management of tumor lysis syndrome with a single fixed dose of rasburicase in Asian lymphoma patients: a case series and literature review","volume":"7","author":"Chiang","year":"2011","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1111\/jcpt.12479-BIB0027|jcpt12479-cit-0027","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4103\/0971-4065.139092","article-title":"Single dose rasburicase in the management of tumor lysis syndrome in childhood acute lymphoblastic leukemia: a case series","volume":"25","author":"Latha","year":"2015","journal-title":"Indian J Nephrol"},{"key":"10.1111\/jcpt.12479-BIB0028|jcpt12479-cit-0028","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1592\/phco.26.6.806","article-title":"Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults","volume":"26","author":"McDonnell","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1111\/jcpt.12479-BIB0029|jcpt12479-cit-0029","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1592\/phco.26.2.242","article-title":"Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy","volume":"26","author":"Hutcherson","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1111\/jcpt.12479-BIB0030|jcpt12479-cit-0030","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1365-2125.2012.04355.x","article-title":"Effectiveness of a single fixed dose of rasburicase 3 mg in the management of tumour lysis syndrome","volume":"75","author":"Coutsouvelis","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/jcpt.12479-BIB0031|jcpt12479-cit-0031","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1365-2710.2008.00994.x","article-title":"Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach","volume":"34","author":"Campara","year":"2009","journal-title":"J Clin Pharm Ther"},{"key":"10.1111\/jcpt.12479-BIB0032|jcpt12479-cit-0032","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/sj.bmt.1705379","article-title":"Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia","volume":"37","author":"Trifilio","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1111\/jcpt.12479-BIB0033|jcpt12479-cit-0033","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1586\/ehm.11.73","article-title":"Rasburicase for the treatment of tumor lysis in hematological malignancies","volume":"5","author":"Malaguarnera","year":"2012","journal-title":"Expert Rev Hematol"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12479","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12479\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T20:34:52Z","timestamp":1718915692000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,25]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12479","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11,25]]}}}